Pmel17: controversial indeed but critical to melanocyte function.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Repeat domains of melanosome matrix protein Pmel17 orthologs form amyloid fibrils at the acidic melanosomal pH.The Journal of biological chemistry · 2011
   Article
2. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2008
   Article
3. Premelanosome amyloid-like fibrils are composed of only golgi-processed forms of Pmel17 that have been proteolytically processed in endosomes.The Journal of biological chemistry · 2008
   Article
4. Genetic effects on coat colour in cattle: dilution of eumelanin and phaeomelanin pigments in an F2-Backcross Charolais x Holstein population.BMC genetics · 2007
   Article

Corrections and comments

• Comment on
  The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function.2005

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as